July 2009, Volume 39 Number 7 , p 60 - 60 [FREE]


  • Jennifer Belavic PharmD


function set_JnlFullText_Print() { metaTag = document.createElement('meta'); metaTag.setAttribute('name','OvidPageId'); metaTag.setAttribute('content','JnlFullText_Print'); head = document.getElementsByTagName('head')[0]; head.appendChild(metaTag); return; } if (window.addEventListener) { // DOM Level 2 Event Module (NS 6+) // Firefox throws an uncaught exception error executing this // code, even though it seems to work. Adding a do nothing // try/catch clause around it for now, since the exection itself // appears to be innocuous try { window.addEventListener('onload',set_JnlFullText_Print(),false); } catch(e) {} } else if (window.attachEvent) { // IE 5+ Event Model window.attachEvent('onload',set_JnlFullText_Print); } // For anything else, just don't add the event Print Close Combination drugs… DOI: 10.1097/01.NURSE.0000357276.71408.1b ISSN: 0360-4039 Accession: 00152193-200907000-00025 Author(s):

Belavic, Jennifer PharmD

Issue: Volume 39(7), July 2009, p ...


Do you know what they contain? Match the names in Section I with the ingredients in Section II.



_____ 1. Simcor (Abbott)


_____ 2. Avandaryl (GlaxoSmithKline)


_____ 3. Azor (Daiichi Sankyo)


_____ 4. Epzicom (GlaxoSmithKline)


_____ 5. BiDil (NitroMed)



a.amlodipine 5 mg, 10 mg; olmesartan medoxomil 20 mg, 40 mg


Combining a calcium channel blocker and an angiotensin receptor blocker, this drug reduces BP more effectively than either drug given alone. Teach patients to change position slowly to prevent orthostatic hypotension.


b.niacin extended-release 500 mg, 750 mg, 1,000 mg; simvastatin 20 mg


This fixed-dose combination antidyslipidemic contains an HMG-Co-A reductase inhibitor (statin) and niacin. It's approved for use in patients with primary hypercholesterolemia or mixed dyslipidemia. Inform your patient that this product may cause flushing, headache, and back pain. Taking aspirin or another nonsteroidal anti-inflammatory drug such as ibuprofen 30 minutes beforehand may decrease flushing.


c.isosorbide dinitrate 20 mg; hydralazine 37.5 mg


This is the first combination product of its kind approved as adjunctive treatment for heart failure in African-American patients. Isosorbide dinitrate is a vasodilator with both arterial and venous effects and hydralazine is primarily an arterial vasodilator. Teach your patient about possible adverse reactions, such as hypotension, headache, and dizziness.


d.rosiglitazone 4 mg, 8 mg; glimepiride 1 mg, 2 mg, 4 mg


A combination of two hypoglycemic drugs, this treatment for type 2 diabetes improves glycemic control. Advise your patient that the drug's full effect may not occur for 2 to 3 months.


e.abacavir 600 mg; lamivudine 300 mg


Comprised of two nucleoside/nucleotide reverse transcriptase inhibitors, this once-daily product is approved to treat HIV. Teach your patient to report a skin rash, unusual fatigue, or jaundice.